NeoGenomics, Inc. a leading oncology testing services company, announced that Tony Zook has officially assumed the role of Chief Executive Officer.
“Tony has a strong command of the healthcare landscape and a deep understanding of the opportunities ahead for NeoGenomics,” said Lynn Tetrault, Chair of the Board. “His experience leading commercial and operational teams, combined with his significant connection to our strategy, make him the right leader to drive our next phase of growth and expand access to critical cancer diagnostics.”
As CEO, Zook will build on NeoGenomics’ momentum while sharpening focus on execution and growth. He will lead the company in delivering diagnostic testing innovation where it’s needed most—within the community oncology setting, where up to 80% of cancer patients receive care. His approach emphasizes operational discipline, strategic partnerships, and expanding access to advanced diagnostics that support precision medicine.
“I’m honored to lead NeoGenomics and excited to help shape the next phase of the company’s journey,” said Zook. “Our strength lies in delivering innovation beyond academic centers and into the community, where most cancer patients are treated. We’re uniquely positioned to translate advances in precision medicine into real-world impact—and I look forward to working with our team to continue expanding that reach in smart, sustainable ways.”
Comments powered by CComment